ABSTRACT
The value of morphologic features to be used prognosing dissemination and survival in skin malignant melanoma is discussed. Single-factor statistical analysis showed tumor thickness, extent of invasion or local spreading, clinico-morphologic pattern, lymphoid-plasmocytic infiltration, mitotic activity and cell composition to be the most reliable in predicting survival and dissemination in clinical stage I malignant melanoma of the skin. These parameters should be evaluated at microscopic evaluation of the tumor. Two-, five- and ten-year prognosis was obtained by multifactorial analysis yielding credibilities of 86.2, 78.5 and 71% for survival and 61.5, 68.7 and 74.3% for lethality, respectively.
Subject(s)
Melanoma/pathology , Skin Neoplasms/pathology , Humans , Melanoma/mortality , Neoplasm Invasiveness , Neoplasm Metastasis , Neoplasm Staging , Prognosis , Skin Neoplasms/mortalitySubject(s)
Foot Diseases/diagnosis , Hand , Melanoma/diagnosis , Skin Neoplasms/diagnosis , Adolescent , Adult , Aged , Child , Child, Preschool , Female , Humans , Male , Middle Aged , PrognosisSubject(s)
Melanoma/pathology , Skin Neoplasms/pathology , Female , Humans , Male , Melanoma/mortality , Prognosis , Skin Neoplasms/mortalitySubject(s)
Melanoma/mortality , Skin Neoplasms/mortality , Adolescent , Adult , Age Factors , Aged , Child , Child, Preschool , Female , Humans , Infant , Male , Middle Aged , Prognosis , Sex FactorsABSTRACT
Out of 3,822 cases of malignant skin melanoma from an unknown primary site, metastases were registered in 53 (1.4%). The male/female ratio was 3:1. The rates of 3-, 5- and 10-year survival were evaluated versus sex, time to treatment, metastatic site and therapeutic modality. The shortest survival was associated with metastasis into cervical lymph nodes, while the longest one (with an overall 3-year survival rate of 40%)--with involvement of a single lymphatic zone. The latter group should be given a complex treatment including a standard regional lymphadenectomy with adjuvant chemo- and immunotherapy. Such treatment resulted in a 3-year survival in 50% of cases. The overall survival rates in patients with metastasis of malignant skin melanoma with an unknown primary site were 29% at 3 years, 26.5%--at 5 and 23.2% at 10 years.
Subject(s)
Melanoma/secondary , Neoplasms, Unknown Primary , Skin Neoplasms/secondary , Adolescent , Adult , Age Factors , Aged , Female , Humans , Lymphatic Metastasis , Male , Melanoma/mortality , Middle Aged , Sex Factors , Skin Neoplasms/mortalityABSTRACT
Out of 2018 patients, skin melanoma occurred in IO2 (5%) cases during pregnancy. Three-, five- and ten year survival was analysed in the latter cases versus term of pregnancy, abortion and the stage of the disease. Also comparison was made between the said group, another 42 females who developed tumors during lactation period and 599 normally-cycling females of reproductive age who were not pregnant when melanoma appeared (controls). Significantly lower 10-year survival was observed in pregnant patients, as compared with those who were not pregnant (p less than 0.05). Five- and ten-year survivals were significantly lower in cases of stage I tumor during the latter half of pregnancy than in skin melanoma patients who were not pregnant (p less than 0.05). Abortion during the first half of pregnancy was found to produce an adverse effect on prognosis in stage I tumor patients while this effect was reversed in stage II tumor. No significant differences were found between 3-, 5- and 10-year survival in melanoma patients who had pregnancies before the disease and those who had not (p greater than 0.05).
